ATE509917T1 - Gamma-secretase-inhibitoren - Google Patents
Gamma-secretase-inhibitorenInfo
- Publication number
- ATE509917T1 ATE509917T1 AT04768519T AT04768519T ATE509917T1 AT E509917 T1 ATE509917 T1 AT E509917T1 AT 04768519 T AT04768519 T AT 04768519T AT 04768519 T AT04768519 T AT 04768519T AT E509917 T1 ATE509917 T1 AT E509917T1
- Authority
- AT
- Austria
- Prior art keywords
- gamma secretase
- secretase inhibitors
- gamma
- secretase
- amyloid
- Prior art date
Links
- 239000003540 gamma secretase inhibitor Substances 0.000 title 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0322340A GB0322340D0 (en) | 2003-09-24 | 2003-09-24 | Therapeutic agents |
| GB0322341A GB0322341D0 (en) | 2003-09-24 | 2003-09-24 | Therapeutic agents |
| PCT/GB2004/003973 WO2005030731A1 (en) | 2003-09-24 | 2004-09-16 | Gamma-secretase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE509917T1 true ATE509917T1 (de) | 2011-06-15 |
Family
ID=34395437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04768519T ATE509917T1 (de) | 2003-09-24 | 2004-09-16 | Gamma-secretase-inhibitoren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7514459B2 (de) |
| EP (1) | EP1667984B1 (de) |
| JP (1) | JP2007506715A (de) |
| AT (1) | ATE509917T1 (de) |
| AU (1) | AU2004276050B2 (de) |
| CA (1) | CA2539042A1 (de) |
| WO (1) | WO2005030731A1 (de) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| JP2008518955A (ja) | 2004-11-02 | 2008-06-05 | ノースウェスタン ユニバーシティ | ピリダジン化合物および方法 |
| ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
| US8242103B2 (en) | 2005-05-19 | 2012-08-14 | Merck Sharp & Dohme Limited | Sulphamides for treatment of cancer |
| CA2644136A1 (en) | 2006-02-27 | 2007-09-07 | The Johns Hopkins University | Cancer treatment with gamma-secretase inhibitors |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2008076556A2 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| EP2142514B1 (de) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thioharnstoffderivate als glutaminylcyclaseinhibitoren |
| EP2291181B9 (de) | 2008-04-18 | 2013-09-11 | University College Dublin National University Of Ireland, Dublin | Captodiamine zur Behandlung von depressionartigen Symptomen |
| AU2009316264B2 (en) | 2008-11-24 | 2016-09-15 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| PE20121172A1 (es) | 2009-10-14 | 2012-09-05 | Merck Sharp & Dohme | Piperidinas sustituidas con actividad en la hdm2 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP3330377A1 (de) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina) |
| US9029341B2 (en) | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| EP2613782B1 (de) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2686313B1 (de) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazolderivate als glutaminylcyclase-hemmer |
| AR087119A1 (es) * | 2011-07-12 | 2014-02-12 | Dow Agrosciences Llc | Composiciones plaguicidas y procesos relacionados |
| EP2770987B1 (de) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Neue verbindungen als erk-hemmer |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| US20150209406A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
| US20150209367A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
| RU2660429C2 (ru) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
| RS56680B1 (sr) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
| KR102196882B1 (ko) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Hdm2 억제제로서의 치환된 이미다조피리딘 |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| EP3407901B1 (de) | 2016-01-29 | 2021-07-21 | Massachusetts Eye & Ear Infirmary | Expansion und differenzierung von innenohrunterstützenden zellen und verfahren zur verwendung davon |
| JP6840774B2 (ja) | 2016-05-16 | 2021-03-10 | ザ ジェネラル ホスピタル コーポレイション | 肺上皮エンジニアリングにおけるヒト気道幹細胞 |
| EP3525785B1 (de) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5-inhibitoren |
| WO2018111926A2 (en) | 2016-12-16 | 2018-06-21 | Inception 3, Inc. | Methods of treating cochlear synaptopathy |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3706747B1 (de) | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US12552826B2 (en) | 2018-08-07 | 2026-02-17 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3833668B1 (de) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| US12595248B2 (en) | 2019-12-17 | 2026-04-07 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2021126731A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US12441730B2 (en) | 2019-12-17 | 2025-10-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| BR112022012015A2 (pt) | 2019-12-17 | 2022-08-30 | Merck Sharp & Dohme Llc | Inibidores de prmt5 |
| US20240116945A1 (en) | 2022-09-02 | 2024-04-11 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
| WO2024091437A1 (en) | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| GEAP202516798A (en) | 2022-12-14 | 2025-10-27 | Merck Sharp & Dohme Llc | Auristatin linker-payloads, pharmaceutical compositions, and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK145080A (da) * | 1979-04-04 | 1980-10-05 | Merck Sharp & Dohme | Fremgangsmaade til fremstilling af aminoderivater af 2-hydroxy-6,9-methano-11-amino-5,6,7,8,9,10-hexahydrobenzocycloocten |
| US4341904A (en) * | 1980-02-19 | 1982-07-27 | Merck & Co., Inc. | Derivatives of 2-hydroxy-6,9-methano-11-amino-5,6,7,8,9,10-hexahydro-benzocyclooctene |
| ES2300119T3 (es) | 1997-02-27 | 2008-06-01 | Takeda Pharmaceutical Company Limited | Compuestos de amina, su produccion y su uso como inhibidores de la produccion de beta-amiloide. |
| WO2001070677A1 (en) * | 2000-03-20 | 2001-09-27 | Merck Sharp & Dohme Limited | Sulphonamido-substituted bridged bicycloalkyl derivatives |
| CA2427206C (en) | 2000-11-02 | 2011-06-28 | Merck Sharp & Dohme Limited | Sulfamides as gamma-secretase inhibitors |
| GB0119152D0 (en) * | 2001-08-06 | 2001-09-26 | Merck Sharp & Dohme | Therapeutic agents |
| GB0209997D0 (en) | 2002-05-01 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0209995D0 (en) * | 2002-05-01 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| EP1503998B1 (de) * | 2002-05-01 | 2009-07-01 | MERCK SHARP & DOHME LTD. | Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase |
| GB0209991D0 (en) | 2002-05-01 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0225475D0 (en) * | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
| GB0225474D0 (en) * | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
| GB0326039D0 (en) * | 2003-11-07 | 2003-12-10 | Merck Sharp & Dohme | Therapeutic agents |
-
2004
- 2004-09-16 US US10/571,717 patent/US7514459B2/en not_active Expired - Fee Related
- 2004-09-16 AU AU2004276050A patent/AU2004276050B2/en not_active Ceased
- 2004-09-16 WO PCT/GB2004/003973 patent/WO2005030731A1/en not_active Ceased
- 2004-09-16 EP EP04768519A patent/EP1667984B1/de not_active Expired - Lifetime
- 2004-09-16 AT AT04768519T patent/ATE509917T1/de not_active IP Right Cessation
- 2004-09-16 CA CA002539042A patent/CA2539042A1/en not_active Abandoned
- 2004-09-16 JP JP2006527458A patent/JP2007506715A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1667984A1 (de) | 2006-06-14 |
| CA2539042A1 (en) | 2005-04-07 |
| US20060293373A1 (en) | 2006-12-28 |
| AU2004276050B2 (en) | 2010-02-25 |
| JP2007506715A (ja) | 2007-03-22 |
| EP1667984B1 (de) | 2011-05-18 |
| US7514459B2 (en) | 2009-04-07 |
| WO2005030731A1 (en) | 2005-04-07 |
| AU2004276050A1 (en) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE509917T1 (de) | Gamma-secretase-inhibitoren | |
| ATE386028T1 (de) | Zyklohexylsulfone als gamma-sekretase-inhibitoren | |
| DE60327438D1 (de) | Amino-substituierte cyclohexan derivate zur behandlung bakterieller infektionen | |
| DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| SG161318A1 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| NO20054369D0 (no) | Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse | |
| IS7620A (is) | Qínólín afleiður og notkun þeirra sem tálma sveppagerla | |
| UY27774A1 (es) | Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona | |
| ATE433963T1 (de) | Fab-i inhibitoren | |
| NO20052362D0 (no) | Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner | |
| ECSP055809A (es) | Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4 | |
| PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
| SG162614A1 (en) | Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors | |
| ECSP055844A (es) | Nuevos compuestos triciclicos | |
| MXPA05001885A (es) | El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica. | |
| CL2007001910A1 (es) | Compuestos derivados de penem; composicion farmaceutica; y uso en el tratamiento de una infeccion bacteriana. | |
| DK1558580T3 (da) | N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner | |
| NO20043445L (no) | Kombinasjonsterapi for behandling av bakterielle infeksjoner | |
| ECSP045405A (es) | Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa | |
| ATE325115T1 (de) | Pyrimidinderivate als selektive cox-2-inhibitoren | |
| ATE556053T1 (de) | Piperidinderivate zur behandlung von alzheimer- krankheit | |
| NO20054670D0 (no) | Behandling av intestinale tilstander med N-2,3,3-tetrametylbisyklo[2.2.1]-heptan-2-amid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |